Michael Randall

Michael Randall

Auto-generated profile, based on publicly available information

Michael Randall

Children's Hospital of Philadelphia, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Cancer Cell
Verified
Journal Article
Closed access
KBKristopher R. Bosse
Kristopher R. Bosse
PRPichai Raman
Pichai Raman
ZZZhongyu Zhu
Zhongyu Zhu
MLMaria Lane
Maria Lane
DMDaniel Martinez
Daniel Martinez
JMJohn M. Maris
John M. Maris

3 May 2016 in Nature Communications
Verified
Journal Article
Open access
EYEungi Yang
Eungi Yang
OTOfelia Tacchelly-Benites
Ofelia Tacchelly-Benites
ZWZhenghan Wang
Zhenghan Wang
MRMichael P. Randall
Michael P. Randall
ATAi Tian
Ai Tian
YAYashi Ahmed
Yashi Ahmed
Wnt/β-catenin signalling directs fundamental processes during metazoan development and can be aberrantly activated in cancer. Wnt stimulation induces the recruitment of the scaffold protein Axin from an inhibitory destruction complex to a stimulatory signalosome. Here we analyse the early effects of Wnt on Axin and find that the ADP-ribose polymerase Tankyrase (Tnks)—known to target Axin for proteolysis—regulates Axin’s rapid transition following Wnt stimulation. We demonstrate that the pool of ADP-ribosylated Axin, which is degraded under basal conditions, increases immediately following Wnt stimulation in both Drosophila and human cells. ADP-ribosylation of Axin enhances its interaction with the Wnt co-receptor LRP6, an essential step in signalosome assembly. We suggest that in addition to controlling Axin levels, Tnks-dependent ADP-ribosylation promotes the reprogramming of Axin following Wnt stimulation; and propose that Tnks inhibition blocks Wnt signalling not only by increasing destruction complex activity, but also by impeding signalosome assembly.

27 March 2018 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
LRLaura E. Ritenour
Laura E. Ritenour
MRMichael P. Randall
Michael P. Randall
KBKristopher R. Bosse
Kristopher R. Bosse
SDSharon J. Diskin
Sharon J. Diskin

1 February 2018 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
AWAnnika L. Windon
Annika L. Windon
ARTURO LOAIZA-BONILLAARTURO LOAIZA-BONILLA
ARTURO LOAIZA-BONILLA
CJChristopher Edward Jensen
Christopher Edward Jensen
MRMichael Randall
Michael Randall
JMJennifer J. D. Morrissette
Jennifer J. D. Morrissette
SSStuti G. Shroff
Stuti G. Shroff
Background: The KRAS oncogene is a driver mutation and is present in greater than 90% of pancreatic ductal adenocarcinomas (PDAC). A subset of these tumors, however, do not harbor mutations in KRAS (wild type KRAS). Studies have shown that patients with mutated KRAS have a poorer survival on first-line gemcitabine-based chemotherapy compared to wild type KRAS. In this study, we examined a cohort of patients with PDAC at our institution who were either wild type or mutant for the KRAS gene and assessed for differences in survival and response to different chemotherapeutic regimens. Methods: We examined clinical records of patients treated at the Abramson Cancer Center of the University of Pennsylvania from 2013 to 2017. Patients with a pancreatic mass and a histologic diagnosis of pancreatic or pancreaticobiliary adenocarcinoma were identified. Thirty-nine patients with PDAC who underwent tumor sequencing at Penn Medicine’s Center for Personalized Diagnostics (CPD) were selected for further study. Twelve patients were identified whose tumors were KRAS wild type. Twenty-seven patients with PDAC whose tumors harbored KRAS mutations were selected as controls (KRAS mutant). Results: We noted a longer overall survival (OS) among KRAS wild type patients compared to KRAS mutant patients (P=0.026). This was independent of the age at diagnosis, patient gender, stage of diagnosis, tumor morphology, mismatch repair (MMR) status, and chemotherapeutic regimen. Conclusions: Similar to previously reported studies, PDAC with a KRAS wild type mutational profile has a better prognosis with a longer OS. This improved prognosis is independent of the protocol utilized in therapy for these patients. Our findings suggest that future clinical trials in pancreatic cancer should take into consideration the presence of KRAS mutations in their pre-planned analysis when assessing the efficacy of a novel therapeutic approach. This may be a crucial factor in trial concepts and outcomes.

6 February 2018 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
OTOfelia Tacchelly-Benites
Ofelia Tacchelly-Benites
ZWZhenghan Wang
Zhenghan Wang
EYEungi Yang
Eungi Yang
HBHassina Benchabane
Hassina Benchabane
ATAi Tian
Ai Tian
YAYashi Ahmed
Yashi Ahmed
The aberrant activation of Wnt signal transduction initiates the development of 90% of colorectal cancers, the majority of which arise from inactivation of the tumor suppressor Adenomatous polyposis coli (APC). In the classical model for Wnt signaling, the primary role of APC is to act, together with the concentration-limiting scaffold protein Axin, in a “destruction complex” that directs the phosphorylation and consequent proteasomal degradation of the transcriptional activator β-catenin, thereby preventing signaling in the Wnt-off state. Following Wnt stimulation, Axin is recruited to a multiprotein “signalosome” required for pathway activation. Whereas it is well-documented that APC is essential in the destruction complex, APC’s role in this complex remains elusive. Here, we demonstrate in Drosophila that Axin exists in two distinct phosphorylation states in Wnt-off and Wnt-on conditions, respectively, that underlie its roles in the destruction complex and signalosome. These two Axin phosphorylation states are catalyzed by glycogen synthase kinase 3 (GSK3), and unexpectedly, completely dependent on APC in both unstimulated and Wnt-stimulated conditions. In a major revision of the classical model, we show that APC is essential not only in the destruction complex, but also for the rapid transition in Axin that occurs after Wnt stimulation and Axin’s subsequent association with the Wnt co-receptor LRP6/Arrow, one of the earliest steps in pathway activation. We propose that this novel requirement for APC in Axin regulation through phosphorylation both prevents signaling in the Wnt-off state and promotes signaling immediately following Wnt stimulation. The Wnt signal transduction pathway directs fundamental cellular processes during development and in homeostasis. Wnt signaling is deregulated in 90% of colorectal cancers, most of which are triggered by inactivation of the tumor suppressor Adenomatous polyposis coli (APC). In the classical model, APC’s sole role in Wnt signaling is to target the transcriptional coactivator β-catenin for phosphorylation and subsequent degradation, and thereby to inhibit signaling in the unstimulated state. However, the mechanisms by which APC functions remain unknown. Herein, we provide evidence in Drosophila that supports a major role for APC in the direct regulation of the scaffold protein Axin in both Wnt-on and Wnt-off conditions. Our results indicate that APC promotes Axin phosphorylation, which is required not only to inhibit signaling in the unstimulated state, but also to activate signaling following Wnt stimulation. These unanticipated findings support a more active and multifaceted role for APC in Wnt signaling than previously known, and force revision of the current model for APC function.

24 February 2016 in mAbs
Verified
Journal Article
Open access
YFYang Feng
Yang Feng
YWYanping Wang
Yanping Wang
ZZZhongyu Zhu
Zhongyu Zhu
WLWei Li
Wei Li
RSRobyn T. Sussman
Robyn T. Sussman
Dimiter DimitrovDimiter Dimitrov
Dimiter Dimitrov
CD56 (NCAM, neural cell adhesion molecule) is over-expressed in many tumor types, including neuroblastoma, multiple myeloma, small cell lung cancer, ovarian cancer, acute myeloid leukemia, NK-T lymphoma, neuroendocrine cancer and pancreatic cancer. Using phage display, we identified 2 high-affinity anti-CD56 human monoclonal antibodies (mAbs), m900 and m906, which bound to spatially separated non-overlapping epitopes with similar affinity (equilibrium dissociation constant 2.9 and 4.5 nM, respectively). m900 bound to the membrane proximal fibronectin type III-like domains, whereas m906 bound to the N-terminal IgG-like domains. m906 induced significant down-regulation of CD56 in 4 neuroblastoma cell lines tested, while m900-induced downregulation of CD56 was much lower. Antibody-drug conjugates (ADCs) made by conjugation with a highly potent pyrrolobenzodiazepine dimer (PBD) exhibited killing activity that correlated with CD56 down-regulation, and to some extent with in vivo binding ability of the antibodies. The m906PBD ADC was much more potent than m900PBD, likely due to higher CD56-mediated downregulation and stronger binding to cells. Treatment with m906PBD ADC resulted in very potent cytotoxicity (IC50: 0.05–1.7 pM). These results suggest a novel approach for targeting CD56-expressing neuroblastoma cells. Further studies in animal models and in humans are needed to find whether these antibodies and their drug conjugates are promising candidate therapeutics.